Dinuclear Cu(II) hypocrellin B complexes with enhanced photonuclease activity.
Yi Sun, Yuan-Jun Hou, Qian-Xiong Zhou, Wan-Hua Lei, Jing-Rong Chen, Xue-Song Wang, Bao-Wen Zhang
Index: Inorg. Chem. 49(21) , 10108-16, (2010)
Full Text: HTML
Abstract
Five new dinuclear Cu(II) complexes were designed and synthesized, using hypocrellin B, a naturally occurring photosensitizer that has received extensive studies as promising photodynamic therapy (PDT) agent, as bridging ligand, and five kinds of diimine ligands, including 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen), 3,4,7,8-tetramethyl-1,10-phenanthroline (tmp), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq), and dipyrido[3,2-a:2',3'-c]phenazene (dppz), as terminal ligands, respectively. The Cu(2+)-HB complexes exhibit improved water solubility, enhanced absorptivity in the phototherapeutic window of 600-900 nm, and increased binding affinity toward dsDNA than their parent HB. The biologically accessible redox potential of Cu(II)/Cu(I) couple renders the five Cu(2+)-HB complexes chemical nuclease activities in the presence of reducing agent such as ascorbic acid. Moreover, the readily available redox potential of Cu(II)/Cu(I) couple switches the photodynamic activity from type II mechanism (singlet oxygen mechanism) for HB to type I mechanism (radical mechanism) for the Cu(2+)-HB complexes. Of the five Cu(2+)-HB complexes, complex 3-5 with terminal diimine ligands of tmp, dpq, and dppz, respectively, can photocleave supercoiled pBR322 DNA more efficiently than HB. These findings open a new avenue for the development of the HB derivatives with higher photodynamic activity and better clinical applicability.
Related Compounds
Related Articles:
Cytotoxic platinum(II) intercalators that incorporate 1R,2R-diaminocyclopentane.
2013-01-28
[Dalton Trans. 42(4) , 918-26, (2013)]
Tetraaqua(3,4,7,8-tetramethyl-1,10-phenanthroline-kappa2N,N')zinc(II) thiosulfate.
2004-09-01
[Acta Crystallogr. C 60(Pt 9) , m451-3, (2004)]
2009-04-20
[Inorg. Chem. 48(8) , 3438-52, (2009)]
1979-10-01
[Methods Find. Exp. Clin. Pharmacol. 1(4) , 239-60, (1979)]
2011-03-14
[Dalton Trans. 40(10) , 2180-9, (2011)]